Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double blind dose-ranging study of ARA 290 in sarcoidosis patients with small fiber neuropathy
2013-003016-45Phase 2Completed
- Sponsor
- Araim Pharmaceuticals
- Start
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in small fiber neuropathy (SFN) and sarcoidosis comparing ARA 290 dose-ranging arm with Placebo arm (2 arms). Primary endpoint: Change in corneal nerve fiber density. Started Aug 2013; status: completed.
02
Drugs
cibinetide
03
Conditions
small fiber neuropathy (SFN)sarcoidosis
Beyond the preview
Go deeper on 2013-003016-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003016-45.